Department of Radiation Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Department of Interventional Radiology, Tata Memorial Hospital, Tata Memorial Centre, Mumbai, Maharashtra, India.
Indian J Med Res. 2024 Feb 1;159(2):232-240. doi: 10.4103/ijmr.ijmr_1171_21. Epub 2024 Apr 4.
There is limited evidence studying the relationship of liver segmental dose and segmental volume changes. The segmental dose thresholds could potentially allow for segmental regeneration after liver stereotactic body radiation therapy (SBRT). Given improved survival in hepatocellular cancer (HCC) and liver metastases and more salvage therapy options, this has become an important clinical question to explore. This study assesses the impact of liver segmental dose on segmental volume changes (gain or loss) after SBRT.
Liver segmental contours were delineated on baseline and serial follow up triphasic computed tomography scans. The volumes of total liver and doses to total liver, uninvolved liver and individual segments were noted. A correlation was evaluated between liver/segmental volume and dose using Pearson's correlation. Furthermore, receiver operator's curve (ROC) analysis was performed to find the segmental dose, i.e . predictive for liver volume loss.
A total of 140 non-tumour liver segments were available for analysis in 21 participants. Overall, 13 participants showed loss of overall liver volume and eight showed gain of overall liver volume. The median dose in segments reporting an increase in volume was 9.1 Gy (7-36 Gy). The median dose in segments losing volume was 15.5 Gy (1-49 Gy). On ROC analysis, segmental dose >11 Gy was associated with volume loss. On univariate analysis, only liver segmental dose contributed to a significant segmental volume loss.
We propose from the findings of this study that in SBRT for large hepatocellular cancer or liver metastases, liver segments should be individually delineated. Furthermore, 3-5 liver segments may be preferentially subjected to <9 Gy to facilitate hepatocyte regeneration. Preferential sparing of uninvolved liver segments may improve outcomes in liver stereotaxyas lower segmental doses were associated with liver regeneration. This may have implications on future liver SBRT planning where segmental doses may be as important as the mean dose.
目前关于肝脏节段剂量与节段体积变化之间关系的研究证据有限。在肝脏立体定向体部放射治疗(SBRT)后,节段剂量阈值可能允许节段再生。由于肝细胞癌(HCC)和肝转移瘤的生存率提高以及更多挽救性治疗选择,这已成为一个需要探索的重要临床问题。本研究评估了 SBRT 后肝脏节段剂量对节段体积变化(增加或减少)的影响。
在基线和连续随访的三期 CT 扫描上勾画肝脏节段轮廓。记录总肝体积和总肝、未受累肝及各节段剂量。使用 Pearson 相关分析评估肝/节段体积与剂量之间的相关性。此外,还进行了接收器操作特征(ROC)曲线分析,以找到预测肝体积损失的节段剂量。
21 名参与者的 140 个非肿瘤性肝段可用于分析。总体而言,13 名参与者的总肝体积减少,8 名参与者的总肝体积增加。体积增加的节段的中位剂量为 9.1 Gy(7-36 Gy)。体积减少的节段的中位剂量为 15.5 Gy(1-49 Gy)。在 ROC 分析中,节段剂量>11 Gy 与体积损失相关。单因素分析显示,只有肝节段剂量与节段体积损失显著相关。
我们根据本研究的结果提出,在大肝癌或肝转移瘤的 SBRT 中,应单独勾画肝脏节段。此外,为了促进肝细胞再生,可能需要将 3-5 个肝段优先接受<9 Gy 的剂量。优先保护未受累的肝段可能会改善肝脏立体定向的治疗效果,因为较低的节段剂量与肝再生相关。这可能对未来的肝脏 SBRT 计划有影响,其中节段剂量可能与平均剂量同样重要。